CI - The Cigna Group
| Previous Close | 263.20 |
| Open | 261.99 |
| Bid | 260.99 x 800 |
| Ask | 261.07 x 800 |
| Day's Range | 255.24 - 262.52 |
| 52 Week Range | 240.11 - 340.11 |
| Volume | |
| Avg. Volume | 1,869,190 |
| Market Cap | 77.359B |
| Beta (5Y Monthly) | 0.63 |
| PE Ratio (TTM) | 11.98 |
| EPS (TTM) | 21.82 |
| Earnings Date | Aug 02, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | 4.92 (1.87%) |
| Ex-Dividend Date | Jun 06, 2023 |
| 1y Target Est | 328.13 |
ZacksCigna (CI) Inks Deal With CHSS to Enhance Specialty Care
Cigna (CI) partners with CarepathRx Health System Solutions to accelerate the delivery of pharmacy care for patients with complex needs.
Simply Wall St.There's A Lot To Like About Cigna Group's (NYSE:CI) Upcoming US$1.23 Dividend
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...
ZacksCigna Group (CI) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Cigna (CI) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
ZacksCI or HUM: Which HMO Stock is Better Placed at the Moment?
Cigna (CI) and Humana (HUM) are well-positioned to expand in the promising HMO space. Let's try to find out which one fares better via comparative evaluation.
ZacksCigna (CI) is a Top Dividend Stock Right Now: Should You Buy?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Cigna (CI) have what it takes? Let's find out.
- Reuters
UPDATE 2-US FTC expands probe into pharmacy benefit managers
The U.S. Federal Trade Commission said it had sought information from two privately held companies that negotiate drug rebates on behalf of pharmacy benefit managers (PBMs) as part of its probe into how PBMs affect pricing of prescription drugs. The two companies, Zinc Health Services and Ascent Health Services, are group purchasing organizations, that negotiate after-market discounts or rebates with drug manufacturers on behalf of PBMs and hold the contracts that govern those rebates.
Business WireAM Best Upgrades Issuer Credit Ratings of The Cigna Group and Most of Its Subsidiaries
OLDWICK, N.J., May 17, 2023--AM Best has upgraded most of the Long-Term Issuer Credit Ratings (Long-Term ICRs) to "a+" (Excellent) from "a" (Excellent) and affirmed the Financial Strength Rating (FSR) of A (Excellent) of the key U.S. life/health subsidiaries, health maintenance organizations and Europe-based insurance companies of The Cigna Group (Cigna) (headquartered in Bloomfield, CT) [NYSE: CI]. The outlook of the Long-Term ICRs has been revised to stable from positive while the outlook of t
ZacksCigna Group (CI) Is a Trending Stock: Facts to Know Before Betting on It
Cigna (CI) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- Reuters
UPDATE 1-Insulin makers testify on Capitol Hill over prices
PBMs negotiate with drugmakers for rebates and lower fees on behalf of employers and other clients, and reimburse pharmacies for prescriptions they dispense. Both sides blame each other for high drug prices. Testifying on Wednesday were the CEOs of major insulin manufacturers Eli Lilly and Co, Novo Nordisk, and Sanofi, which together control 90% of the U.S. market, and top PBM executives from CVS Health Corp, Cigna Group's Express Scripts, and UnitedHealth Group Inc's Optum RX, which control 80% of the prescription drug market.
Yahoo FinanceWhy indie pharmacies, with the help of the likes of Mark Cuban, are on the rise
Independent pharmacies and startups such as Cigna's Express Scripts and Mark Cuban's Cost Plus Drugs are partnering up to address a coverage gap for some Americans.
ZacksThe Zacks Analyst Blog Highlights Eli Lilly, Verizon Communications, United Parcel Service, Advanced Micro Devices and The Cigna Group
Eli Lilly, Verizon Communications, United Parcel Service, Advanced Micro Devices and The Cigna Group are part of the Zacks Analyst Blog.
- Reuters
CORRECTED-Pharma CEOs to testify in U.S. Senate hearing on insulin prices
The leaders of major insulin makers and pharmacy benefit managers (PBMs) are set to blame each other on Wednesday in their testimonies during a U.S. Senate committee hearing on making the life-saving drug more affordable. PBMs negotiate with drugmakers for rebates and lower fees on behalf of employers and other clients, and reimburse pharmacies for prescriptions they dispense. Both sides blame each other for high drug prices.
ZacksTop Stock Reports for Eli Lilly, Verizon Communications & United Parcel Service
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Verizon Communications Inc. (VZ) and United Parcel Service, Inc. (UPS).
ZacksEverQuote (EVER) Q1 Earnings Beat on Lower Operating Expenses
EverQuote (EVER) expects total revenues of $70-$75 million for the second quarter of 2023.
Motley FoolCigna Group (CI) Q1 2023 Earnings Call Transcript
Ladies and gentlemen, thank you for standing by for the Cigna Group's first quarter 2023 results review. With me on the line this morning are David Cordani, the Cigna Group's chairman and chief executive officer; and Brian Evanko, chief financial officer.
- Zacks
Cigna (CI) Q1 Earnings Surpass Estimates, Ups '23 EPS View
Cigna's (CI) first-quarter 2023 results indicate a strong contribution to revenues from Evernorth Health Services and Cigna Healthcare businesses. Management currently expects adjusted EPS to be a minimum of $24.70 in 2023.
ZacksHere's What Key Metrics Tell Us About Cigna (CI) Q1 Earnings
While the top- and bottom-line numbers for Cigna (CI) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ZacksCigna (CI) Surpasses Q1 Earnings and Revenue Estimates
Cigna (CI) delivered earnings and revenue surprises of 3.44% and 2.11%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ReutersCigna's health insurance strength drives profit forecast raise
(Reuters) -Cigna Group on Friday raised its annual profit forecast after lower medical costs at the company's health insurance business helped it beat estimates in the first quarter, lifting shares 7.5% in morning trade. The health insurer also cut the midpoint of its 2023 medical cost ratio - or spending on claims as a percentage of premiums - by 10 basis points to between 81.5% and 82.3%. Peers including UnitedHealth and Humana also beat profit estimates and raised forecasts this quarter thanks to strength in their government-backed plans and low medical costs.
- Reuters
Cigna lifts profit view after lower medical costs drive Q1 beat
Cigna Group on Friday raised its annual profit forecast after strong growth and lower medical costs at the company's health insurance business helped it beat estimates in the first quarter. One of the oldest health insurers in the U.S., Cigna saw its medical cost ratio - or spending on claims as a percentage of premiums - fall to 81.3% from 81.5% thanks to higher premiums and lower COVID-19 costs. Several other health insurers including UnitedHealth and Humana also beat profit estimates and raised forecasts this quarter on strength in their government-backed plans and low medical costs.
ZacksThis is Why Cigna (CI) is a Great Dividend Stock
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Cigna (CI) have what it takes? Let's find out.
- Zacks
Why Earnings Season Could Be Great for Cigna Group (CI)
Cigna Group (CI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ZacksCan Cigna's (CI) Q1 Earnings Beat on Medical Customers Growth?
The first-quarter results of Cigna (CI) are likely to reflect an expanding customer base and growth in specialty pharmacy services.
